Clinical evaluation of transrectal power Doppler imaging in the detection of prostate cancer

To evaluate the clinical usefulness of power Doppler imaging (PDI) compared to gray-scale transrectal ultrasound (TRUS) in the detection of prostate cancer. A total of 101 men with abnormally high serum prostate specific antigen (PSA) levels and/or abnormal digital rectal examination (DRE) findings were assessed using TRUS and PDI. Random systematic sextant and bilateral far lateral prostate biopsies were performed in all cases. In addition, when TRUS revealed a hypoechoic lesion or PDI revealed a hypervascular lesion (HVL), these lesions were directly biopsied. Of the 101 patients, 48 (47.5%), 42 (41.5%) and 42 (41.5%) were suspicious of having prostate cancer by DRE, TRUS and PDI, respectively. Prostate needle biopsy revealed prostate cancer in 39 patients (38.6%) and benign prostatic diseases in 62 patients (61.4%). If prostate needle biopsy was avoided when PDI was negative, then PDI eliminated the need for biopsy in 59 of the 101 patients (rate of biopsy procedures saved: 58.4%) and missed only 8 (13.6%) prostate cancers. Moreover, in 63 patients with intermediate PSA (3–10 ng/ml), the rate of biopsy procedures saved by DRE, TRUS, and PDI was 60.3%, 65.1%, and 68.3%, respectively, and the rate of cancers missed was 26.3%, 19.5%, and 14.0%, respectively. In a total of 826 specimens of TRUS-guided prostate biopsy, 126 (15.3%) specimens had adenocarcinoma. Site by site based analysis of the present series revealed 34.1% of prostate cancer sites were isoechoic and hypervascular. On a site by site basis, PDI had better sensitivity, specificity, positive predictive value and negative predictive value than TRUS. In 48 patients without abnormal DRE findings, on a site by site basis, the sensitivities of TRUS and PDI were 22.9% and 34.4%, respectively. Gleason score was associated with a positive rate of PDI on both a patient basis and site by site basis. From these results, on a patient basis, we conclude that PDI was helpful in the indication for prostate biopsy for all patients or patients with intermediate PSA level. On a site by site basis, PDI may be able to select prostate cancer sites at biopsy, in particular inpatients without abnormal DRE findings.

[1]  H. Watanabe,et al.  [A pilot study of mass screening program for prostatic cancer by means of prostate specific antigen (PSA) filter paper method]. , 1997, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

[2]  M. Rifkin,et al.  Prostate: techniques, results, and potential applications of color Doppler US scanning. , 1993, Radiology.

[3]  A comparison of transrectal ultrasonography and endorectal magnetic resonance imaging in the local staging of prostatic carcinoma , 1999, BJU international.

[4]  N. Oakley.  Transrectal power Doppler imaging in the detection of prostate cancer , 2001 .

[5]  O. Ukimura,et al.  Possible use of transrectal power Doppler imaging as an indicator of microvascular density of prostate cancer. , 2001, Urology.

[6]  J M Rubin,et al.  Power Doppler US: a potentially useful alternative to mean frequency-based color Doppler US. , 1994, Radiology.

[7]  J. Rubin,et al.  Prostate cancer: diagnosis with color Doppler sonography with histologic correlation of each biopsy site. , 1995, Radiology.

[8]  W. Lees,et al.  Prostate cancer and the role of color Doppler US. , 1993, Radiology.

[9]  J. Cho,et al.  Diffuse prostatic lesions: role of color Doppler and power Doppler ultrasonography. , 1998, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[10]  J Drago,et al.  The American cancer society national prostate cancer detection project. Findings on the detection of early prostate cancer in 2425 men , 1991, Cancer.

[11]  O. Franco,et al.  The usefulness of power Doppler ultrasonography for diagnosing prostate cancer: histological correlation of each biopsy site , 2000, BJU international.

[12]  F. Frauscher,et al.  High-frequency Doppler US of the prostate: effect of patient position. , 2002, Radiology.

[13]  R G Aarnink,et al.  Three‐dimensional contrast‐enhanced power Doppler ultrasonography and conventional examination methods: the value of diagnostic predictors of prostate cancer , 2000, BJU international.

[14]  M. Brawer,et al.  Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity , 1994, Cancer.

[15]  M. Frydenberg,et al.  Prostatic cancer: role of color Doppler imaging in transrectal sonography. , 1998, AJR. American journal of roentgenology.

[16]  J. Heiken,et al.  Evaluation of the prostate and prostatic carcinoma with gadolinium-enhanced endorectal coil MR imaging. , 1993, Radiology.

[17]  W. Cooner,et al.  Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. , 1990, The Journal of urology.

[18]  S. Shariat,et al.  Characteristics of normal prostate vascular anatomy as displayed by power Doppler , 2001, The Prostate.

[19]  T. D. de Reijke,et al.  Considerations Regarding Prostate Biopsies , 1998, European Urology.

[20]  C C Schulman,et al.  PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. , 1999, Urology.

[21]  Hiroki Watanabe,et al.  前立腺特異抗原 (PSA) 濾紙法による前立腺がん検診の試行 , 1997 .

[22]  T. Drewniak,et al.  Vascular angiographic asymmetry on three‐dimensional transrectal power Doppler ultrasonography in patients with organ‐confined prostate cancer , 2002, BJU international.

[23]  J. Sauvain,et al.  Echo-Doppler puissance et nodules hypoéchogènes de la prostate périphérique: perspectives et limites. , 1997 .

[24]  J. Weyler,et al.  Screening for prostatic cancer. , 1993, British medical journal.

[25]  P. Scardino,et al.  The appearance of prostate cancer on transrectal ultrasonography: correlation of imaging and pathological examinations. , 1989, The Journal of urology.

[26]  M. K. Atilla,et al.  The role of power Doppler ultrasonography in the diagnosis of prostate cancer: a preliminary study. , 1998, British journal of urology.

[27]  Transrectal Ultrasound of the Prostate: Innovations and Future Applications , 1998 .

[28]  R. Bree.  The role of color Doppler and staging biopsies in prostate cancer detection. , 1997, Urology.

[29]  J. Oesterling,et al.  Prostate specific antigen: a decade of discovery--what we have learned and where we are going. , 1999, The Journal of urology.

[30]  H Watanabe,et al.  Kinetic study of tumor blood flow in prostatic cancer using power Doppler imaging. , 1999, Ultrasound in medicine & biology.

[31]  Normal Prostate Gland: Examination with Color Doppler US , 1995 .

[32]  F. Hinman.  Screening for prostatic carcinoma. , 1991, The Journal of urology.

[33]  Hessel Wijkstra,et al.  Quantitative microbubble enhanced transrectal ultrasound as a tool for monitoring hormonal treatment of prostate carcinoma , 2002, The Prostate.

[34]  O. Hélénon,et al.  Color Doppler-guided prostate biopsies in 591 patients with an elevated serum PSA level: impact on Gleason score for nonpalpable lesions. , 1997, Urology.

[35]  Hessel Wijkstra,et al.  The Application of Three–Dimensional Contrast–Enhanced Ultrasound to Measure Volume of Affected Tissue after HIFU Treatment for Localized Prostate Cancer , 2000, European Urology.